Recursion Pharmaceuticals Inc.
Clinical trials sponsored by Recursion Pharmaceuticals Inc., explained in plain language.
-
Drug trial for recurring gut infection halted early
Disease control TerminatedThis study tested an oral drug called REC-3964 to see if it could prevent repeat C. diff infections in adults who had just finished treatment for one. It was a Phase 2 trial that ended early when the company sponsoring it decided to stop, which they said was not due to safety pro…
Phase: PHASE2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Apr 04, 2026 00:35 UTC
-
Targeted drug trial for advanced cancers halted early
Disease control TerminatedThis study tested an oral drug called REC-4881 in adults with advanced solid tumors that had spread and carried specific gene changes (AXIN1 or APC). The goal was to see if the drug was safe and could help control the cancer in people who had already tried standard treatments. Th…
Phase: PHASE2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Drug trial halted for rare brain tumor condition
Disease control TerminatedThis study tested an investigational drug called REC-2282 to see if it could slow or stop the growth of brain tumors (meningiomas) in people with Neurofibromatosis Type 2 (NF2). It involved about 25 participants aged 12 and older with progressive tumors. The trial was designed in…
Phase: PHASE2, PHASE3 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC